This study is looking at how well a once-weekly injection called lonapegsomatropin (SKYTROFA®) works compared to a daily injection called somatropin. It's for children and teenagers aged 2 to 17 who have short stature or growth problems due to conditions like Turner Syndrome, SHOX gene mutation, Idiopathic Short Stature (unexplained short stature), or being Small for Gestational Age (born smaller than average). The main goal is to see how much children grow in a year (Annualized Height Velocity) after 52 weeks of treatment. About 186 participants will join this study, which is taking place in several countries, including the United States.

Study design

This interventional study will enroll approximately 186 participants. Participants will be randomly assigned to receive either lonapegsomatropin for 2 years or somatropin for 1 year followed by lonapegsomatropin for 1 year.

What's involved

Participants will receive either a once-weekly subcutaneous injection of lonapegsomatropin or a once-daily subcutaneous injection of somatropin. The study duration for each participant will be either 1 or 2 years, depending on the assigned treatment group.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, Annualized Height Velocity, is measured at 52 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.